What We Have Gained from Ibogaine: α3ß4 Nicotinic Acetylcholine Receptor Inhibitors as Treatments for Substance Use Disorders.
J Med Chem
; 66(1): 107-121, 2023 01 12.
Article
in En
| MEDLINE
| ID: mdl-36440853
ABSTRACT
For decades, ibogaineâthe main psychoactive alkaloid found in Tabernanthe ibogaâhas been investigated as a possible treatment for substance use disorders (SUDs) due to its purported ability to interrupt the addictive properties of multiple drugs of abuse. Of the numerous pharmacological actions of ibogaine and its derivatives, the inhibition of α3ß4 nicotinic acetylcholine receptors (nAChRs), represents a probable mechanism of action for their apparent anti-addictive activity. In this Perspective, we examine several classes of compounds that have been discovered and developed to target α3ß4 nAChRs. Specifically, by focusing on compounds that have proven efficacious in pre-clinical models of drug abuse and have been evaluated clinically, we highlight the promising potential of the α3ß4 nAChRs as viable targets to treat a wide array of SUDs. Additionally, we discuss the challenges faced by the existing classes of α3ß4 nAChR ligands that must be overcome to develop them into therapeutic treatments.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Receptors, Nicotinic
/
Substance-Related Disorders
/
Ibogaine
Limits:
Humans
Language:
En
Journal:
J Med Chem
Journal subject:
QUIMICA
Year:
2023
Document type:
Article
Affiliation country:
United States